HEAT SHOCK PROTEIN 27 IN LARYNGEAL SQUAMOUS CELL CANCER TREATMENT

  • O. V. Horolec State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
  • V. A. Kashirin State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
  • L. L. Voroncova State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
Keywords: laryngeal cancer, HSP27

Abstract

Heat shock protein 27 (HSP27) belongs to a family of ATP-independent chaperones and plays a fundamental role in cell physiology in various disease states, including cancer. So, it was found that serum HSP27 levels were significantly increased in patients with various tumors, but their significance in laryngeal carcinoma is not well defined.

Purpose of the study. Determination and comparison HSP27 serum levels at different stages of special treatment methods in laryngeal cancer patients.

Materials and methods. The studies were conducted in 31 patients of laryngeal cancer of T2–3 N0 M0 categories before treatment and at its various stages. The serum HSP27 levels analysis was carried out using the «ELISA» diagnostics test system by enzyme immunoassay.

Results. The serum HSP27 levels in patients before treatment and with various types of special treatment are statistically significantly higher than the control values. There was a decrease in serum HSP27 levels in patients after removal of the neoplasm and a slight increase in serum HSP27 levels after completion of radiation therapy.

Comparison of initial serum HSP27 values in patients with subsequent relapse of the disease with initial serum HSP27 levels in patients with positive treatment outcomes did not reveal statistically significant differences.

Conclusion. The serum HSP27 levels in laryngeal cancer patients are elevated and remain so at all treatment stages. Initial level of serum HSP27 cannot predict tumor recurrence.

References

Li Z, Srivastava P. Heat-shock proteins. Curr Protoc Immunol. 2004; Appendix 1: Appendix 1T. DOI: 10.1002/0471142735.ima01ts58.

Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005; 10 (2): 86–103. DOI: 10.1379/CSC-99R.

Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol. 2012; 44 (10): 1646–1656. DOI: 10.1016/j.biocel.2012.04.010.

Lianos GD, Alexiou GA, Mangano A et al. The role of heat shock proteins in cancer. Cancer Cell. 2015; 360 (2): 114–118. DOI: 10.1016/j.canlet.2015.02.026.

Saini J, Sharma PK. Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer. Curr Drug Targets. 2018; 19 (13): 1478–1490. DOI: 10.2174/1389450118666170823121248.

Chen J.H., Chen L.M., Xu L.Y. et al. Expression and significance of heat shock proteins in esophagal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2006; 28 (10): 758–761.

Choi S-K, Kam H, Kim K-Y et al. Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment? Cancers (Basel). 2019; 1 (8): 1195. DOI: 10.3390/cancers11081195.

Lee MS, Lee J, Lee S. Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget. 2018; 9 (8): 7961–7974. DOI: 10.18632/oncotarget.24091.

Gruden G, Carucci P, Lolli V et al. Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. Cell Stress Chaperones. 2013; 18 (2): 235–241. DOI: 10.1007/s12192-012-0377-8.

Soleimani A, Jalili-Nik M, Avan A et al. The role of HSP27 in the development of drug resistance of gastrointestinal malignancies: Current status and perspectives. J Cell Physiol. 2019; 234 (6): 8241–8248. DOI: 10.1002/jcp.27666.

Lee JH, Sun D, Cho KJ et al. Overexpression of human 27 kDa heat shock protein in laryngeal cancer cells confers chemoresistance associated with cell growth delay. J Cancer Res Clin Oncol. 2007; 133 (1): 37–46. DOI: 10.1007/s00432-006-0143-3.

Kaigorodova EV, Zavyalova MV, Bychkov VA et al. Functional state of the Hsp27 chaperone as a molecular marker of an unfavorable course of larynx cancer. Cancer Biomark. 2016; 17 (2): 145–153. DOI: 10.3233/CBM-160625.

Karam J, Fadous-Khalifé MC, Tannous R et al. Role of Krüppel-like factor 4 and heat shock protein 27 in cancer of the larynx. Mol Clin Oncol. 2017; 7 (5): 808–814. DOI: 10.3892/mco.2017.1412.

Nazhmudinov II, Saidov MZ. Oncomarkers and heat shock proteins in chronic hypertrophic laryngitis as probable predictors of malignancy of laryngeal epithelial cells. Opukholi GOLOVY i SHEI. 2017; 7 (2): 51–91. DOI: 10.17650/2222-1468-2017-7-2-81-91.

Published
2020-09-20
How to Cite
Horolec, O. V., Kashirin, V. A., & Voroncova, L. L. (2020). HEAT SHOCK PROTEIN 27 IN LARYNGEAL SQUAMOUS CELL CANCER TREATMENT. Modern Medical Technology, (3(46), 12-14. https://doi.org/10.34287/MMT.3(46).2020.2
Section
Original research